Meta-analysis examines CBD responder rates in pediatric drug-resistant epilepsy

A systematic review and meta-analysis of cannabidiol in pediatric drug-resistant epilepsies was published online in Epilepsy Research on 15 October 2026. Andrea D. Praticò authored the analysis, which targets two endpoints clinicians most often dispute: seizure responder rates and the consistency of neurobehavioral outcome reporting.

The study population is children with drug-resistant epilepsy (defined as failure of adequate trials of at least two tolerated, appropriately chosen antiseizure medications). Cannabidiol (CBD, a non-psychoactive cannabinoid of Cannabis sativa) has held an expanding place in pediatric epileptology since randomized trials in Dravet syndrome and Lennox-Gastaut syndrome supported regulatory approval of a purified formulation.

What does the review examine?

Praticò's analysis pools published studies to estimate how many treated children meet the conventional responder criterion — typically a 50 percent or greater reduction in seizure frequency — and to evaluate whether trials report neurobehavioral outcomes in a standardized way. Neurobehavioral domains include cognition, behavior, sleep and quality of life, areas that families frequently rank as highly as seizure control.

The choice of endpoints matters for clinical neurophysiology practice. Seizure responder rates in CBD studies derive from diary-based counts correlated with scalp EEG (electroencephalography recorded from electrodes on the scalp) findings, and outcome adjudication in the monitoring unit often depends on that same pairing. A meta-analysis that quantifies pooled responder rates gives epilepsy centers a benchmark for counseling parents before initiation.

The second aim — appraisal of neurobehavioral outcome reporting — addresses a recognized gap. Reviews of antiseizure medications have repeatedly found heterogeneous or absent neurobehavioral measurement across trials, which complicates comparison between agents and formulation of treatment guidelines.

Context for the reading room

Pediatric drug-resistant epilepsy accounts for roughly 30 percent of childhood epilepsy cases, and these patients generate a disproportionate share of long-term video-EEG monitoring admissions. Readers should note that this work is a synthesis of previously published human data, not a new trial; no new patient cohort was enrolled.

No detailed numerical results, cohort sizes or device information appear in the publication notice now available. The full text in Epilepsia-caliber outlets will specify which study designs entered the pooled estimate and how the authors handled variation in CBD dose, formulation and concomitant medication.

Clinicians and EEG technologists who counsel families on cannabinoid therapy will find the review relevant to expectation-setting: pooled responder figures anchor the discussion of probability of benefit, while the appraisal of neurobehavioral reporting indicates how much confidence the field can place in cognitive and behavioral claims. Full results are available in Epilepsy Research, with the article accessible online as of 15 October 2026.